Clinical, laboratory and densitometric comparison of patients with coxarthrosis and femoral neck fractures.

Comparação clínica, laboratorial e densitométrica de pacientes com coxartrose e com fraturas do colo femoral.

Leandro de Freitas Spinelli^{1,2,3}; Fernando Pagnussato^{4,5}; Tiango Aguiar Ribeiro^{4,6}; Felipe Silva Guareze^{4,5}; Marta Goldman Feder⁴; Carlos Alberto de Souza Macedo⁷; Luis Fernando Moreira, TCBC-RS⁴; Carlos Roberto Galia^{4,5,7}

ABSTRACT

Objective: to compare clinical, laboratory and densitometric data from patients with osteoarthrosis and femoral neck fractures. **Methods:** we conducted a cross-sectional study of patients with femoral neck fracture and hip osteoarthrosis submitted to hip arthroplasty. We collected clinical, laboratory and densitometric data. **Results:** we included 53 patients, 22 with femoral neck fractures and 31 with osteoarthrosis. Patients with femoral neck fractures were older than patients with osteoarthrosis, with lower BMI values, bone mineral density and palmar grip strength (sarcopenic patients), being more neurologically impaired and presenting a worse ASA score. Among the various biochemical parameters analyzed, we found statistically significant differences in total serum calcium, ionized calcium, vitamin D, free thyroxine, erythrocytes, hemoglobin, hematocrit, total white blood cells, neutrophils, lymphocytes and creatinine between the two groups. Other hormones analyzed and biochemical parameters did not differ significantly, although they showed trends between the two groups. **Conclusion:** patients with femoral neck fractures are older than patients with osteoarthrosis, have a lower weight and BMI, are more debilitated, many with anemia and reduced bone mass, and have a significant decrease in total calcium, ionized calcium, vitamin D and creatinine and a significant increase in free thyroxine.

Keywords: Arthroplasty, Replacement, Hip. Osteoarthritis. Femoral Neck Fractures. Hip Fractures. Densitometry.

INTRODUCTION

Osteoarthrosis (OA) is a chronic and degenerative disease that affects synovial joints, including the hip¹. It is basically characterized by the wear of the cartilage that covers the surfaces of the joint formed by the femoral head and the acetabulum. It is considered as having a multifactorial etiology, therefore being influenced by several factors².

Fractures of the femoral neck occur more frequently in elderly patients, being uncommon in patients under 60 years of age. Most of these fractures occur in female patients, the incidence increasing exponentially with age. The risk of a hip fracture is high, ranging from 40% to 50% in women over 60 years and 13% to 22% in men³. Biochemical markers may reflect the status of bone metabolism and provide information on bone remodeling (turnover)⁴, which is often altered in skeletal disorders. Few studies have investigated the potential differences in the characteristics of bone markers. Resmini *et al.* observed changes in serum calcium and PTH levels in the fracture group when compared with the control group (or with osteoarthrosis). All patients were vitamin D3-deficient, with no difference between groups⁵.

The objective of this study is to compare clinical, laboratory and densitometric data of patients who underwent hip arthroplasty for neck fractures and for hip osteoarthrosis.

^{1 -} Federal University of Rio Grande do Sul (UFRGS), Post-Graduation Programme in Medicine: Surgical Sciences - Porto Alegre - Rio Grande do Sul - Brasil. 2 - Irmandade da Santa Casa de Misericórdia de Porto Alegre, Department of Orthopedics - Porto Alegre - Rio Grande do Sul - Brasil. 3 - University of Passo Fundo, Laboratory of Bioengineering, Biomechanics and Biomaterials - Passo Fundo - Rio Grande do Sul - Brasil. 4 - Hospital de Clinicas de Porto Alegre (HCPA), Research Group in Hip, Biomaterials and Tissue Bank - Porto Alegre - Rio Grande do Sul - Brasil. 5 - Hospital de Clinicas de Porto Alegre (HCPA), Tissue Bank - Porto Alegre - Rio Grande do Sul - Brasil. 6 - Federal University of Santa Maria (UFSM), Department of Surgery - Santa Maria - Rio Grande do Sul - Brasil. 7 - Federal University of Rio Grande do Sul (UFRGS), Department of Surgery - Porto Alegre - Rio Grande do Sul - Brasil.

METHODS

The research project was submitted to, and approved by, the Scientific Committee and the Ethics in Research Committee of our institution (CAAE 05745712.0.0000.5327). We clarified all subjects invited to participate about the research and its objectives prior to performing the surgical procedure and collecting material for blood analysis. The consenting subjects signed an Informed Consent Term. We collected the information between March 2014 and October 2016.

The research consists in a cross-sectional study of patients affected by femoral neck fractures and by osteoarthrosis of the hip that underwent hip arthroplasty. We included 53 patients, 22 with fracture and 31 with osteoarthrosis. We selected patients sequentially as they underwent total hip arthroplasty, at the same time as we checked the inclusion and exclusion criteria.

As inclusion criterion, we considered patients older than 60 years submitted to hip arthroplasty, having fracture of the femoral neck or hip osteoarthrosis as cause. As exclusion criteria, we considered those patients who did not wish to participate in the study and who did not sign the Informed Consent Term, those with femoral fractures other than of the femoral neck, with dysplasias and deformities of the femur or acetabulum, previously operated on the hip for other reasons, patients with osteoarthrosis associated with osteonecrosis, metabolic disorders (Morquio syndrome, etc.), patients with rheumatic diseases (Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus), those using bisphosphonates, hormone replacement therapy, glucocorticoid use in the month prior to surgery, and supplementation of calcium, vitamin B12, folate or vitamin D.

We questioned and examined the patients the day before the surgical procedure. We collected information directly with the patient, such as demographic data and the cause of arthroplasty (fracture of the femoral neck or arthrosis), and measured the strength of the patients' palmar grip through a dynamometer regulated and measured by INMETRO. We collected blood samples for measuring serum total calcium, ionic calcium, sodium, potassium, phosphorus, complete blood count, thyrotropin (TSH), free thyroxine (T4L), 25-OH-vitamin D, aldosterone, androstenedione, estradiol, folliclestimulating hormone (FSH), luteinizing hormone (LH), parathyroid hormone (PTH), progesterone, total testosterone, alkaline phosphatase, creatinine, urea, TP and TTPA. We performed densitometries in the immediate postoperative period.

We performed data analysis using the Statistical Package for The Social Sciences (SPSS 18.0) software. We determined the means and dispersion of the quantitative variables and the proportions of the qualitative ones. We assessed homogeneity with the Kolmogorov-Smirnov test. For analysis of possible differences, we used the Student's t, the chi-square or the ANOVA tests. We used the Mann-Whitney test to identify differences in non-parametric variables. We considered p<0.05 as statistically significant.

RESULTS

We evaluated 22 patients with fracture and 31 with hip osteoarthrosis. Tables 1 and 2 show the relations of the surgical intervention with gender, age and categorized age. In the fractures group, we observed that the majority of the patients were female (68.2%) and the mean age was higher than in the arthrosis group. There was no statistically significant difference between genders (p>0.05), but there was for age between groups (p=0.005).

Table 3 shows patients' clinical data, with a higher age range in patients with fracture, as well as lower weight, lower body mass index (BMI) and lower palmar grip strength (PGS) in the right and left hands compared with patients with osteoarthrosis, all with statistical significance. The only parameter that did not differ significantly between groups was height.

Table 4 shows the comorbidities: neurological disease (Parkinson's, Alzheimer's and dementia) was significant, as well as previous surgeries. The use of tobacco (p=0.377) and alcohol (p=0.280) did not present significant differences. With respect to the ASA score, the number of ASA I, II, III and IV patients was 1, 8, 12 and 1, respectively, among patients with fractures, and 0, 25, 6 and 0 among patients with osteoarthritis, with statistical significance (p=0.002).

Among the various laboratory parameters evaluated, we found a statistically significant difference for total and ionic serum calcium, 25-OHvitamin D, erythrocytes, hemoglobin, hematocrit, total leukocytes, lymphocytes, basophils, creatinine and free thyroxine. Other biochemical parameters showed tendencies between the two groups, such as alkaline phosphatase and testosterone, but were not statistically significant (Table 5).

Table 1. Demographic	data relating the reaso	on for surgery with	sex and age.
TUDIC I. Demographic	add relating the rease	ni ioi suigery with	JCA unu uge.

	Fracture N=22	Osteoarthrosis N=31
Gender*		
Male	7 (31.8)	13 (41.9)
Female	15 (68.2)	18 (58.1)
Age**		
Male	78.3±11.8	69.8±8.0
Female	75.1±12.0	65.9±6.5

* number of patients (percentage); ** average ± standard deviation.

Age range	Fracture**			Osteoarthritis**
(years)	N*	N*=22	N*	N*=31
60-69	8	63.5±3.1	21	63.2±3.0
70-79	4	73.5±1.7	7	74.0±2.7
≥80	10	87.2±5.8	3	82.7±2.3

* N= number of patients; ** average ± standard deviation.

Table 3. Clinica	l parameters evaluated.
------------------	-------------------------

Parameter	Fracture**	Osteoarthritis**	p*	
Age (years)	76.09±11.76	67.55±7.30	0.005	
Weight (kg)	64.32±12.09	74.02±11.46	0.005	
Height (m)	1.64±0.06	1.65±0.07	0.198	
BMI (kg/m ²)	24.02±4.29	26.83±3.41	0.010	
Right PGS (Kgf)*	21.67±9.26	29.96±8.40	0.016	
Left PGS (Kgf) *	19.39±10.11	28.37±8.61	0.015	

* PGS: palmar grip strength; ** average ± standard deviation.

0.014

0.395

0.767

1.000

0.985

Fable 4. Comorbidities assessed.		
Comorbidity	p	
Diabetes	0.720	
Systemic arterial hypertension	0.218	
Congestive heart failure	0.087	
Arrhythmia	0.066	
Acute myocardial infarction	0.133	
Transient ischemic accident	0.087	
Ischemic vascular stroke	0.087	
Hemorrhagic vascular stroke	*	
Asthma	*	
Chronic obstructive pulmonary disease	0.395	
Previous surgery	0.015	

Tá

Neurological diseases

Previous history of cancer

Number of comorbidities

Kidney disease

Other diseases

* Not enough data.

Parameter	Fracture*	Arthrosis*	References	p**
lonic calcium (mg/dl)	4.88±0.43	5.27±0.39	4.0-4.8	0.003**
Total calcium (mg/dl)	8.55±1.04	9.64±0.83	8.6-10.0	0.000**
Sodium (mEq/l)	140.09±3.19	140.35±2.64	136.0-145.0	0.744
Phosphorus (mg/dl)	3.97±0.83	3.63±0.60	2.5-4.5	0.093
Potassium (mEq/l)	4.52±0.50	4.37±0.55	3.5-5.1	0.108
Chlorides (mEq/l)	101.50±4.91	101.81±4.28	98.0-107.0	0.885
Alkaline phosphatase (U/I)	96.55±45.37	86.53±29.70	35.0-104.0	0,331
25-OH-vitamin D (ng/ml)	14.73±9.71	21.60±7.37	30-100	0.005**
Creatinine (mg/dl)	0.87±0.37	0.99±0.34	0.5-0.9	0.039**
Urea (mg/ml)	53.33±24.68	45.38±13.56	16.0-48.0	0.425
Erythrocytes (x10 ⁶ /µl)	3.99±0.76	4.49±0.58	4.0-5.4	0.015**
Hemoglobin (g/dl)	11.95±2.09	13.32±1.85	11.6-15.6	0.015**
Hematocrit (%)	36.30±6.14	39.95±4.99	36.0-48.0	0.021**
MCHC (g/dl)	32.91±0.78	33.41±1.20	30.5-37.2	0.096
MCV (fl)	91.28±4.70	89.06±4.70	80.0-98.0	0.098
MCH (pg)	30.01±1.69	29.67±1.80	27.0-32.0	0.483
RDW (%)	14.15±1.63	13.87±1.10	up to 15.0	0.569
Total leukocytes (x10³/µl)	9.34±2.32	7.26±2.25	3.6-11.0	0.002**

continuation...

Spinelli

Parameter Fracture* Arthrosis* References p** Segmented (x10%µ) 67.92±11.61 57.74±11.29 45.0-70.0 0.002** Lymphocytes (x10%µ) 19.14±9.78 29.41±7.36 20.0-50.0 0.000** Basophis (x10%µ) 0.25±0.7 0.53±0.31 0.0-7.0 0.607 Koncrytes (x10%µ) 8.84±2.13 8.09±2.40 2.0-10.0 0.057 Monocytes (x10%µ) 254.77±112.39 253.23±61.68 150.0-400.0 0.907 Platelets (x10%µ) 254.77±112.39 253.23±61.68 10.50-640.0 0.907 TP (seconds) 1.04±0.10 1.03±0.05 up to 1.2 0.816 TP (seconds) 2.6.93±2.78 2.7.43±2.98 2.0.27.40 0.705 Thyrotropin (TSH) (uUMi) 3.04±3.07 2.0.74±2.08 0.27.42 0.701 Presentoris (neg/dl) 1.44±0.25 1.25±0.24 0.93-1.0 0.11** Parathropio formome (PTH) (pp/m) 1.93±1.45** 16.67±1.5.26*** Men 0.42* Aldosterone (ng/m) 1.94±1.45** 0.24±0.20**					
Segmented (x10³µl) 67.92±11.61 57.74±11.29 45.0-70.0 0.002** Lymphocytes (x10³µl) 19.14±9.78 29.41±7.36 20.0-50.0 0.000** Basophils (x10³µl) 0.25±0.17 0.53±0.31 0.0-7.0 0.607 Monocytes (x10³µl) 4.02±3.75 2.95±1.67 0.0-7.0 0.607 Monocytes (x10³µl) 254.77±112.39 253.23±61.68 150.0-400.0 0.127 Platelets (x10³µl) 254.77±112.39 253.23±61.68 150.0-400.0 0.539 TP (seconds) 1.04±0.10 1.03±0.05 up to 1.2 0.816 TPA (seconds) 2.6.93±2.78 27.43±2.98 25.0-34.0 0.539 Thyrotropin (TSH) (uU/ml) 3.30±3.07 3.07±3.04 0.93-1.70 0.011* Parathyroid hormone (PTH) (spm) 9.33±0.45*7* 12.5±0.24 0.93-1.70 0.01** Parathyroid hormone (PTH) (spm) 1.49±1.27 0.92±0.67 0.6-3.1 0.128 Aldosterone (ng/ml) 1.91±1.45** 1.657±1.52.6**** Men 0.476 0.30±0.7** 0.32±0.27*** <td< td=""><td>Parameter</td><td>Fracture*</td><td>Arthrosis*</td><td>References</td><td>p**</td></td<>	Parameter	Fracture*	Arthrosis*	References	p**
Lymphocytes (x10 ³ /µl) 19.14±9.78 29.41±7.36 20.0-50.0 0.000** Basophils (x10 ³ /µl) 0.25±0.17 0.53±0.31 0.0-3.0 0.000* Eosinophils (x10 ³ /µl) 4.02±3.75 2.95±1.67 0.0-7.0 0.607 Monocytes (x10 ³ /µl) 8.84±2.13 8.09±2.40 2.0-10.0 0.127 Platelets (x10 ³ /µl) 254.77±112.39 253.23±61.68 150.0-400.0 0.950 TP (seconds) 1.04±0.10 1.03±0.05 up to 1.2 0.816 TTPA (seconds) 26.93±2.78 27.43±2.98 25.0-34.0 0.539 Thyrotropin (TSH) (uUl/ml) 3.0±3.07 3.07±3.04 0.27-4.20 0.705 Free thyroxine (ng/dl) 1.44±0.25 1.25±0.24 0.93-1.70 0.011** Parathyroid hormone (PTH) (pg/ml) 85.30±47.52 82.84±47.47 15.0-68.3 0.824 Aldosterone (ng/dl) 9.03±12.39 10.3±5.8.65 2.5-39.2 0.262 Androstenedione (ng/ml) 1.93±1.045*** 16.7±15.26*** Men 0.827 0.30±0.27*** 0.28±0.31***	Segmented (x10³/µl)	67.92±11.61	57.74±11.29	45.0-70.0	0.002**
Basophils (x10 ³ /µl) 0.25±0.17 0.53±0.31 0.0-3.0 0.000** Eosinophils (x10 ³ /µl) 4.02±3.75 2.95±1.67 0.0-7.0 0.607 Monocytes (x10 ³ /µl) 8.84±2.13 8.09±2.40 2.0-10.0 0.127 Platelets (x10 ³ /µl) 254.77±112.39 253.23±61.68 150.0-400.0 0.950 TP (seconds) 1.04±0.10 1.03±0.05 Ucntrol 13s 0.907 INR 1.04±0.10 1.03±0.05 Up to 1.2 0.816 TP (seconds) 26.93±2.78 27.43±2.98 25.0-34.0 0.539 Thyrotropin (TSH) (uUl/ml) 3.30±3.07 3.07±3.04 0.27-4.20 0.011** Parathyroid hormone (PTH) (pg/ml) 85.30±47.52 82.84±47.47 15.0-68.3 0.824 Aldosterone (ng/dl) 1.49±1.27 0.92±0.67 0.6-3.1 0.123 Etradiol (pg/ml) 1.93±1.045*** 16.67±15.26*** Men 0.476 0.30±0.27*** 0.28±0.31*** 0.24±0.20** Moren (post menopause) 0.10-8 Progesterone (ng/ml) 1.00±1.54*** 1.57±2.0	Lymphocytes (x10³/µl)	19.14±9.78	29.41±7.36	20.0-50.0	0.000**
Eosinophils (x10³/µl) 4.02±3.75 2.95±1.67 0.0-7.0 0,607 Monocytes (x10³/µl) 8.84±2.13 8.09±2.40 2.0-10.0 0.127 Platelets (x10³/µl) 254.77±112.39 253.23±61.68 150.0-400.0 0.950 TP (seconds) 12.55±1.18 12.58±0.72 Control 13s 0.907 INR 1.04±0.10 1.03±0.05 up to 1.2 0.816 TTPA (seconds) 26.93±2.78 27.43±2.98 25.0-34.0 0.539 Thyrotropin (TSH) (uUl/ml) 3.03±3.07 3.07±3.04 0.274.20 0.705 Free thyroxine (ng/dl) 1.44±0.25 1.25±0.24 0.93-1.70 0.011** Parathyroid hormone (PTH) (pg/ml) 85.30±47.52 82.84±47.47 15.0-68.3 0.824 Aldosterone (ng/dl) 9.03±12.39 10.35±8.65 2.5-39.2 0.262 Androstenedione (ng/ml) 1.49±1.27 0.92±0.67 0.6-3.1 0.123 Estradiol (pg/ml) 1.93±0.45*** 16.67±15.26*** Men 0.476 0.30±0.17* 0.33±0.42* 0.2-1.4 0.1-	Basophils (x10³/µl)	0.25±0.17	0.53±0.31	0.0-3.0	0.000**
Monocytes (x10³/µl) 8.84±2.13 8.09±2.40 2.0-10.0 0.127 Platelets (x10³/µl) 254.77±112.39 253.23±61.68 150.0-400.0 0.950 TP (seconds) 12.55±1.18 12.58±0.72 Control 13s 0.907 INR 1.04±0.10 1.03±0.05 up to 1.2 0.816 TTPA (seconds) 26.93±2.78 27.43±2.98 25.0-34.0 0.539 Thyrotropin (TSH) (uUI/ml) 3.30±3.07 3.07±3.04 0.27-4.20 0.705 Free thyroxine (ng/dl) 1.44±0.25 1.25±0.24 0.93-1.70 0.011** Parathyroid hormone (PTH) (pg/ml) 85.30±47.52 82.84±47.47 15.0-68.3 0.824 Aldosterone (ng/dl) 9.03±12.39 10.35±8.65 2.5-39.2 0.262 Androstenedione (ng/ml) 1.94±1.27 0.92±0.67 0.6-3.1 0.123 Estradiol (pg/ml) 1.93±0.45*** 16.67±15.26*** Men 0.27±0.27* Progesterone (ng/ml) 0.30±0.7** 0.28±0.31** Men 0.22±1.4 0.29±0.31* 0.21±0.27* 0.36±1.7* 0.36±1.7*	Eosinophils (x10³/µl)	4.02±3.75	2.95±1.67	0.0-7.0	0,607
Platelets (x10³/µl) 254.77±112.39 253.23±61.68 150.0-400.0 0.950 TP (seconds) 12.55±1.18 12.58±0.72 Control 13s 0.907 INR 1.04±0.10 1.03±0.05 up to 1.2 0.816 TTPA (seconds) 26.93±2.78 27.43±2.98 25.0-34.0 0.539 Thyrotropin (TSH) (uU/ml) 3.30±3.07 3.07±3.04 0.27-4.20 0.705 Free thyroxine (ng/dl) 1.44±0.25 1.25±0.24 0.93-1.70 0.011** Parathyroid hormone (PTH) (pg/ml) 85.30±47.52 82.84±47.47 15.0-68.3 0.824 Aldosterone (ng/dl) 9.03±12.39 10.35±8.65 2.5-39.2 0.262 Androstenedione (ng/ml) 1.49±1.27 0.92±0.67 0.6-3.1 0.123 Progesterone (ng/ml) 1.93±10.45*** 16.67±15.26*** Men 0.476 0.30±0.27**** 0.28±0.31**** Men 0.827 0.24±0.20** Moren (post menopause) 0.1-0.8 0.1-0.8 0.1-0.8 0.1-0.8 0.1-0.8 0.30±0.17** 0.28±0.31**** Men 0.287 0.3-0.41	Monocytes (x10³/µl)	8.84±2.13	8.09±2.40	2.0-10.0	0.127
TP (seconds) 12.55±1.18 12.58±0.72 Control 13s 0.907 INR 1.04±0.10 1.03±0.05 up to 1.2 0.816 TTPA (seconds) 26.93±2.78 27.43±2.98 25.0-34.0 0.539 Thyrotropin (TSH) (uU/ml) 3.30±3.07 3.07±3.04 0.27-4.20 0.705 Free thyroxine (ng/dl) 1.44±0.25 1.25±0.24 0.93-1.70 0.011** Parathyroid hormone (PTH) (pg/ml) 85.30±47.52 82.84±47.47 15.0-68.3 0.824 Aldosterone (ng/dl) 9.03±12.39 10.35±8.65 2.5-39.2 0.262 Androstenedione (ng/ml) 1.49±1.27 0.92±0.67 0.6-3.1 0.123 Estradiol (pg/ml) 19.38±10.45*** 16.67±15.26*** Men 0.476 26.33±6.01" 30.89±14.27" 7.63-42.6 0.92±0.67 0.6-3.1 0.123 Progesterone (ng/ml) 0.30±0.27*** 0.28±0.31*** Men 0.827 0.30±0.17" 0.33±0.42" 0.2-1.4 0.2-1.4 0.2-1.4 0.2-1.4 0.2-1.4 0.3-0.41 0.19±0.19" 0.16±0.14" Noren (post menopause) 0.13-0-0.41 0.3-0.41 0.	Platelets (x10 ³ /µl)	254.77±112.39	253.23±61.68	150.0-400.0	0.950
INR 1.04±0.10 1.03±0.05 up to 1.2 0.816 TTPA (seconds) 26.93±2.78 27.43±2.98 25.0-34.0 0.539 Thyrotropin (TSH) (uUl/ml) 3.30±3.07 3.07±3.04 0.274.20 0.705 Free thyroxine (ng/dl) 1.44±0.25 1.25±0.24 0.93-1.70 0.011** Parathyroid hormone (PTH) (pg/ml) 85.30±47.52 82.84±47.47 15.0-68.3 0.824 Aldosterone (ng/dl) 9.03±12.39 10.35±8.65 2.5-39.2 0.262 Androstenedione (ng/ml) 1.49±1.27 0.92±0.67 0.6-3.1 0.123 Estradiol (pg/ml) 19.38±10.45*** 16.67±15.26*** Men 0.476 26.33±6.01** 7.19±5.29(e) Women (post menopause) 7.63-42.6 0.476 0.30±0.77* 0.33±0.42* 0.21.4 Women (post menopause) 7.01-10.8 0.29±0.31(e) 0.24±0.20(e) 0.10±1.54*** Men 0.287 0.19±0.19*** 1.57±2.06*** Men 0.287 0.36±1.76* 0.30-0.41 0.30-0.41 0.30-0.41 0.30-0.41	TP (seconds)	12.55±1.18	12.58±0.72	Control 13s	0.907
TTPA (seconds) 26.93±2.78 27.43±2.98 25.0-34.0 0.539 Thyrotropin (TSH) (uU/ml) 3.30±3.07 3.07±3.04 0.274.20 0.705 Free thyroxine (ng/dl) 1.44±0.25 1.25±0.24 0.93±1.70 0.011** Parathyroid hormone (PTH) (ng/ml) 85.30±47.52 82.84±47.47 15.0-68.3 0.824 Aldosterone (ng/dl) 9.03±12.39 10.35±8.65 2.5-39.2 0.262 Androstenedione (ng/ml) 1.49±1.27 0.92±0.67 0.6-3.1 0.123 Estradiol (pg/ml) 19.38±10.45*** 16.67±15.26*** Men 0.476 7.63-42.6 10.123 0.30±0.27*** 0.38±14.27* 7.63-42.6 Women (post menopause) 0.50-54.7 Progesterone (ng/ml) 0.30±0.27*** 0.28±0.31*** Men 0.827 0.30±0.27*** 0.28±0.31*** Men 0.827 0.30±0.27*** 0.36±0.27** 0.10±1.54*** 0.10±1.54*** 0.10±0.14*** Women (post menopause) 0.1-0.8 0.19±0.19** 1.00±1.54*** 1.57±2.06**** Men 0.287 0.36±1.76* 0.10±0.14*** 0.030±0.1 0.36±0.17** 0.36±1.76**	INR	1.04±0.10	1.03±0.05	up to 1.2	0.816
Thyrotropin (TSH) (uUV/ml) 3.30±3.07 3.07±3.04 0.27-4.20 0.705 Free thyroxine (ng/dl) 1.44±0.25 1.25±0.24 0.93-1.70 0.011** Parathyroid hormone (PTH) (pg/ml) 85.30±47.52 82.84±47.47 15.0-68.3 0.824 Aldosterone (ng/dl) 9.03±12.39 10.35±8.65 2.5-39.2 0.262 Androstenedione (ng/ml) 1.49±1.27 0.92±0.67 0.6-3.1 0.123 Estradiol (pg/ml) 19.38±10.45*** 16.67±15.26*** Men 0.476 26.33±6.01" 30.88±14.27" 7.63-42.6 Women (post menopause) <5.0-54.7	TTPA (seconds)	26.93±2.78	27.43±2.98	25.0-34.0	0.539
Free thyroxine (ng/dl) 1.44±0.25 1.25±0.24 0.93±1.70 0.011** Parathyroid hormone (PTH) (pg/m) 85.30±47.52 82.84±47.47 15.0-68.3 0.824 Aldosterone (ng/dl) 9.03±12.39 10.35±8.65 2.5-39.2 0.262 Androstenedione (ng/ml) 1.49±1.27 0.92±0.67 0.6-3.1 0.123 Estradiol (pg/ml) 19.38±10.45*** 16.67±15.26*** Men 0.476 26.33±6.01* 30.88±14.27* 7.63-42.6 Men 0.476 26.33±6.01* 0.30±0.27*** 0.28±0.31*** Men 0.827 0.30±0.27*** 0.33±0.42** 0.2-1.4 0.2-1.4 0.2-1.4 0.29±0.31(**) 0.30±0.17** 0.33±0.42** 0.2-1.4 0.2-1.4 0.10±1.54*** 1.57±2.06*** Men 0.287 0.10±1.54*** 1.57±2.06*** Men 0.287 0.10±1.54*** 1.57±2.06*** Men 0.287 0.10±1.54*** 1.57±2.06*** Men 0.295 0.110*** 1.64±1.75* 1.68±1.76** 1.93-7.40 0.10±1.54*** 1.87±2.92** 1.87±9.97** 1.5	Thyrotropin (TSH) (uUI/ml)	3.30±3.07	3.07±3.04	0.27-4.20	0.705
Parathyroid hormone (PTH) (pg/ml) 85.30±47.52 82.84±47.47 15.0-68.3 0.824 Aldosterone (ng/dl) 9.03±12.39 10.35±8.65 2.5-39.2 0.262 Androstenedione (ng/ml) 1.49±1.27 0.92±0.67 0.6-3.1 0.123 Estradiol (pg/ml) 19.38±10.45*** 16.67±15.26*** Men 0,476 26.33±6.01# 30.88±14.27# 7.63-42.6 Women (post menopause) 26.33±0.01# 0.30±0.27*** 0.28±0.31*** Men 0.827 0.30±0.17# 0.33±0.42# 0.2-1.4 0.2-1.4 0.2-1.4 0.29±0.31(**) 0.24±0.20(*) Women (post menopause) 0.1-0.8 0.28* 7.63-42.6 Nen 0.28* 0.2-1.4 0.29* 0.21* 0.29±0.31(*) 0.34±0.20(*) Women (post menopause) 0.1-0.8 0.28* 0.10±1.54*** 1.57±2.06*** Men 0.287 0.30±0.17* 0.19±0.19## 1.00±1.54*** 1.57±2.06*** Men 0.28* (mlU/ml) 1.8.47±21.95* 10.87±9.97* 1.5-12.4 </td <td>Free thyroxine (ng/dl)</td> <td>1.44±0.25</td> <td>1.25±0.24</td> <td>0.93-1.70</td> <td>0.011**</td>	Free thyroxine (ng/dl)	1.44±0.25	1.25±0.24	0.93-1.70	0.011**
Aldosterone (ng/dl) 9.03 ± 12.39 10.35 ± 8.65 $2.5-39.2$ 0.262 Androstenedione (ng/ml) 1.49 ± 1.27 0.92 ± 0.67 $0.6-3.1$ 0.123 Estradiol (pg/ml) $19.38\pm10.45^{***}$ $16.67\pm15.26^{***}$ Men 0.476 $26.33\pm6.01^{#}$ $30.88\pm14.27^{#}$ $7.63-42.6$ Women (post menopause) $< 5.0-54.7$ $5.0-54.7$ Progesterone (ng/ml) $0.30\pm0.27^{***}$ $0.28\pm0.31^{***}$ Men 0.827 $0.30\pm0.17^{#}$ $0.33\pm0.42^{#}$ $0.2-1.4$ $0.29\pm0.31^{(e)}$ $0.24\pm0.20^{(e)}$ Women (post menopause) $0.1-0.8$ Testosterone (ng/ml) $1.00\pm1.54^{***}$ $1.57\pm2.06^{***}$ Men 0.287 $0.1-0.8$ $0.24\pm0.20^{(e)}$ $0.1-0.8$ $0.30\pm0.17^{#}$ $0.24\pm0.20^{(e)}$ Testosterone (ng/ml) $1.00\pm1.54^{***}$ $1.57\pm2.06^{***}$ Men 0.287 $0.1-0.8$ $0.19\pm0.19^{##}$ $0.16\pm0.14^{##}$ $0.03-0.41$ 0.495 Follicle-stimulating hormone (FSH) $42.89\pm28.57^{***}$ $49.83\pm40.48^{***}$ Men 0.495 (mlU/ml) $18.91\pm14.88^{***}$ $26.23\pm20.55^{***}$ Men 0.495 Luteinizing hormone (LH) (mlU/ml) $18.91\pm14.88^{***}$ $26.23\pm20.55^{***}$ Men 0.162 $15.49\pm18.67^{#}$ $10.88\pm9.97^{#}$ $1.7-8.6$ Women (post menopause) $25.8-134.8$ 0.162 Luteinizing hormone (LH) (mlU/ml) $18.91\pm14.88^{***}$ $26.23\pm20.55^{***}$ Men 0.162 $7.7-58.5$ $7.7-58.5$ Men 0.162 $7.7-58.5$ $7.7-58.5$ Men	Parathyroid hormone (PTH) (pg/ml)	85.30±47.52	82.84±47.47	15.0-68.3	0.824
Androstenedione (ng/ml) 1.49 ± 1.27 0.92 ± 0.67 $0.6-3.1$ 0.123 Estradiol (pg/ml) $19.38\pm10.45^{***}$ $16.67\pm15.26^{***}$ Men 0.476 $26.33\pm6.01^{#}$ $30.88\pm14.27^{#}$ $7.63-42.6$ Women (post menopause) $<5.0-54.7$ $0.30\pm0.27^{***}$ $0.28\pm0.31^{***}$ Men 0.827 Progesterone (ng/ml) $0.30\pm0.27^{***}$ $0.28\pm0.31^{***}$ Men 0.827 $0.21.4$ $0.29\pm0.31^{(e)}$ $0.24\pm0.20^{(e)}$ Women (post menopause) $0.1-0.8$ $0.1-0.8$ Testosterone (ng/ml) $1.00\pm1.54^{***}$ $1.57\pm2.06^{***}$ Men 0.287 $0.19\pm0.19^{##}$ $0.6\pm0.14^{##}$ $0.93-0.41$ 0.287 Follicle-stimulating hormone (FSH) $42.89\pm28.57^{***}$ $49.83\pm40.48^{***}$ Men 0.495 (mlU/ml) $18.91\pm14.88^{***}$ $26.23\pm20.55^{***}$ Men 0.495 Luteinizing hormone (LH) (mlU/ml) $18.91\pm14.88^{***}$ $26.23\pm20.55^{***}$ Men 0.162 $1.5.49\pm18.67^{#}$ $10.88\pm9.97^{#}$ $1.7-8.6$ 0.162 $2.50\pm13.2^{0##}$ $25.5\pm13.2^{0##}$ $1.7-8.6$ 0.162	Aldosterone (ng/dl)	9.03±12.39	10.35±8.65	2.5-39.2	0.262
$ \begin{array}{c} \mbox{Estradiol (pg/ml)} & 19.38\pm10.45^{***} \\ 26.33\pm6.01^{\#} \\ 16.13\pm10.62^{(e)} & 7.19\pm5.29^{(e)} \\ 16.13\pm10.62^{(e)} & 7.19\pm5.29^{(e)} \\ 7.03\pm42.6 \\ 7.03\pm42.6 \\ 7.03\pm42.6 \\ 7.02\pm1.4 \\ 7.02\pm1.4 \\ 7.02\pm1.4 \\ 7.10\pm1.4 \\$	Androstenedione (ng/ml)	1.49±1.27	0.92±0.67	0.6-3.1	0.123
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Estradiol (pg/ml)	19.38±10.45***	16.67±15.26***	Men	0,476
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		26.33±6.01#	30.88±14.27#	7.63-42.6	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		16.13±10.62 ^(e)	7.19±5.29 ^(e)	Women (post menopause)	
Progesterone (ng/ml) $0.30\pm0.2/***$ $0.28\pm0.31^{***}$ Men 0.827 $0.30\pm0.17^{#}$ $0.33\pm0.42^{\#}$ $0.2-1.4$ $0.2-1.4$ $0.29\pm0.31^{(e)}$ $0.24\pm0.20^{(e)}$ Women (post menopause) $0.1-0.8$ $0.1-0.8$ $0.1-0.8$ $0.1-0.8$ $0.1-0.8$ Testosterone (ng/ml) $1.00\pm1.54^{***}$ $1.57\pm2.06^{***}$ Men 0.287 $0.19\pm0.19^{\#}$ $0.16\pm0.14^{\#\#}$ Women (post menopause) $0.03-0.41$ Follicle-stimulating hormone (FSH) $42.89\pm28.57^{***}$ $49.83\pm40.48^{***}$ Men 0.495 (mIU/ml) $18.47\pm2.195^{\#}$ $10.87\pm9.97^{\#}$ $1.5-12.4$ 0.162 Luteinizing hormone (LH) (mIU/ml) $18.91\pm14.88^{***}$ $26.23\pm20.55^{***}$ Men 0.162 Luteinizing hormone (LH) (mIU/ml) $18.91\pm14.88^{***}$ $26.23\pm20.55^{***}$ Men 0.162 $0.50\pm13.2^{0\#}$ $36.47\pm19.45^{\#}$ Women (post menopause) $27.58.5$				<5.0-54.7	0.007
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Progesterone (ng/ml)	0.30±0.27*** 0.30±0.17#	0.28±0.31*** 0.23±0.42#	Nien	0.827
$\begin{array}{c} \text{Testosterone (ng/ml)} & 1.00 \pm 1.54^{***} & 1.57 \pm 2.06^{***} & \text{Men} & 0.287 \\ 2.74 \pm 1.75^{\#} & 3.68 \pm 1.76^{\#} & 1.93 - 7.40 \\ 0.19 \pm 0.19^{\#\#} & 0.16 \pm 0.14^{\#\#} & \text{Women (post menopause)} \\ 0.03 - 0.41 \\ \end{array}$ Follicle-stimulating hormone (FSH) $\begin{array}{c} 42.89 \pm 28.57^{***} & 49.83 \pm 40.48^{***} & \text{Men} & 0,495 \\ (\text{mIU/ml}) & 18.47 \pm 21.95^{\#} & 10.87 \pm 9.97^{\#} & 1.5 - 12.4 \\ 54.29 \pm 24.08^{\#\#} & 73.21 \pm 34.21^{\#\#} & \text{Women (post menopause)} \\ 25.8 - 134.8 \\ \text{Luteinizing hormone (LH) (mIU/ml)} & 18.91 \pm 14.88^{***} & 26.23 \pm 20.55^{***} & \text{Men} & 0.162 \\ 15.49 \pm 18.67^{\#} & 10.88 \pm 9.97^{\#} & 1.7 - 8.6 \\ 20.50 \pm 13.2^{0^{\#\#}} & 36.47 \pm 19.45^{\#\#} & \text{Women (post menopause)} \\ 7.7 - 58.5 \\ \end{array}$		0.29+0.31 ^(e)	0.24 ± 0.42	Women (post menopause)	
Testosterone (ng/ml) $1.00\pm1.54^{***}$ $2.74\pm1.75"0.19\pm0.19^{\#}1.57\pm2.06^{***}3.68\pm1.76"0.16\pm0.14^{\#}Men1.93-7.40Women (post menopause)0.03-0.410.287Follicle-stimulating hormone (FSH)(mlU/ml)42.89\pm28.57^{***}18.47\pm21.95"54.29\pm24.08^{\##}49.83\pm40.48^{***}10.87\pm9.97"73.21\pm34.21^{\##}MenVomen (post menopause)25.8-134.80.49525.8-134.8Luteinizing hormone (LH) (mlU/ml)18.91\pm14.88^{***}15.49\pm18.67"20.50\pm13.2^{0\##}26.23\pm20.55^{***}10.88\pm9.97"36.47\pm19.45^{\##}MenVomen (post menopause)1.7-8.6Women (post menopause)7.7-58.50.162$				0.1-0.8	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Testosterone (ng/ml)	1.00±1.54***	1.57±2.06***	Men	0.287
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	-	2.74±1.75 [#]	3.68±1.76 [#]	1.93-7.40	
Follicle-stimulating hormone (FSH) $42.89\pm28.57^{***}$ $49.83\pm40.48^{***}$ Men 0,495 (mIU/ml) $18.47\pm21.95^{\#}$ $10.87\pm9.97^{\#}$ $1.5-12.4$ $54.29\pm24.08^{\#\#}$ $73.21\pm34.21^{\#\#}$ Women (post menopause) 25.8-134.8 Luteinizing hormone (LH) (mIU/ml) $18.91\pm14.88^{***}$ $26.23\pm20.55^{***}$ Men 0.162 $15.49\pm18.67^{\#}$ $10.88\pm9.97^{\#}$ $1.7-8.6$ $20.50\pm13.2^{0\#\#}$ $36.47\pm19.45^{\#\#}$ Women (post menopause) 77-58.5		0.19±0.19 ^{##}	0.16±0.14##	Women (post menopause)	
Follicle-stimulating normone (FSH) $42.89\pm28.57^{***}$ $49.83\pm40.48^{***}$ Men $0,495$ (mIU/ml) $18.47\pm21.95^{\#}$ $10.87\pm9.97^{\#}$ $1.5-12.4$ $54.29\pm24.08^{\#\#}$ $73.21\pm34.21^{\#\#}$ Women (post menopause) $25.8-134.8$ $26.23\pm20.55^{***}$ Men 0.162 Luteinizing hormone (LH) (mIU/ml) $18.91\pm14.88^{***}$ $26.23\pm20.55^{***}$ Men 0.162 $15.49\pm18.67^{\#}$ $10.88\pm9.97^{\#}$ $1.7-8.6$ $20.50\pm13.2^{0\#\#}$ $36.47\pm19.45^{\#\#}$ Women (post menopause) $7.7-58.5$		42 00 . 20 57+++	10 07 . 10 10+++	0.03-0.41	0.405
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	(mil l/ml)	42.89±28.57^^^ 1877+21.95#	49.83±40.48^^^ 10.87+9.97#	IVIEN 1 5-12 /	0,495
25.8-134.8 Luteinizing hormone (LH) (mIU/ml) 18.91±14.88*** 26.23±20.55*** Men 0.162 15.49±18.67 [#] 10.88±9.97 [#] 1.7-8.6 20.50±13.2 ^{0##} 36.47±19.45 ^{##} Women (post menopause) 7.7-58.5		54.29±24.08 ^{##}	73.21±34.21##	Women (post menopause)	
Luteinizing hormone (LH) (mIU/ml) 18.91±14.88*** 26.23±20.55*** Men 0.162 15.49±18.67# 10.88±9.97# 1.7-8.6 20.50±13.2 ^{o##} 36.47±19.45 ^{##} Women (post menopause) 7 7-58 5				25.8-134.8	
15.49±18.67 [#] 10.88±9.97 [#] 1.7-8.6 20.50±13.2 ^{0##} 36.47±19.45 ^{##} Women (post menopause) 7 7-58 5	Luteinizing hormone (LH) (mIU/ml)	18.91±14.88***	26.23±20.55***	Men	0.162
20.50±13.2 ^{°##} 36.47±19.45 ^{##} Women (post menopause) 7 7-58 5		15.49±18.67#	10.88±9.97#	1.7-8.6	
\cdot \cdot $ \cdot$ \cdot \cdot		20.50±13.2 ^{0##}	36.4/±19.45##	VVomen (post menopause) 7 7-58 5	

continuation...

* mean ± standard deviation; ** values with p statistically significant; *** mean ± standard deviation among patients in the group (osteoarthritis or fracture); #mean values ± standard deviation between men in the same group; ##mean ± standard deviation among women in the same group. # mean values ± standard deviation between men in the same group; ## mean ± standard deviation between men in the same group; # mean ± standard deviation between men in the same group; # mean ± standard deviation between men in the same group; # mean ± standard deviation between men in the same group; # mean ± standard

Table 6 shows the values obtained through densitometry. The group with femoral neck fractures presented inferior bone mineral density (BMD), both

in the femoral neck and in the lumbar spine region, as well as for the Tscore and Zscore values, all with statistical significance.

able of bolle densitometry.					
Parameter	Fracture	Arthrosis	Р		
BMD* L1-L4 (g/cm ²)	0.945±0.150	1.098±0.149	0.010		
BMD* femoral neck (g/cm ²)	0.677±0.162	0.974±0.151	0.000		
Tscore	-2.700±1.09	-0.837±1.00	0.000		
7score	-0 855+0 99	0.141+1.03	0.012		

Table 6. Bone densitometry.

* BMD: Bone mineral density.

DISCUSSION

Aging is a natural and physiological process that occurs in human beings. Due to it, each individual experiences emotional, psychological and environmental experiences that make it unique and individual⁶. Although old age is not synonymous with illness and inactivity, aging may be accompanied by chronic and multiple diseases, depending on the economic context, social and cultural development of the individual. In this sense, the physiological changes, when added to the other diseases, weaken the functional capacity of the elderly, compromising their quality of life. Osteoarthrosis is one of these chronic diseases that affects the elderly, presenting a multifactorial etiology². The genetic component and obesity⁷, age⁸, cellularity at articulation⁶, degree of apoptosis⁹, gender and hormones¹⁰ and morphology¹¹ have been mentioned.

Epidemiological studies have identified numerous risk factors for femoral neck fractures, such as BMI below 18.5, low exposure to sunlight, low recreational activity, smoking, previous history of osteoporotic fracture, maternal history of hip fracture, and corticosteroid treatment¹². In addition, 70% of patients with femoral neck fractures have ASA III or IV at the time of fracture³. In the present study, we also found a lower BMI in patients with femoral neck fractures, with a higher mean age, being 68.2% of female patients, 59% with ASA III or IV. We did not observe differences for smoking and alcohol use in our sample. The acute use of corticoid was an exclusion factor.

The reduction of bone mass caused by osteoporosis has an unequivocal relationship with hip fracture and is present in more than 84% of patients with fracture of the femoral neck. Only one standard deviation doubles the risk of hip fractures³. In this study, we also observed lower mineral density in patients with fractures compared to those with hip osteoarthrosis.

Bone diseases alter the production pattern of biochemical markers. Diseases leading to osteopenia tend to increase the relationship between reabsorption markers and formation markers, as appears to be the case in osteoporosis¹³. Vitamin D deficiency states are characterized by a change in osteoblast differentiation, with a disproportionate increase in levels of alkaline phosphatase¹⁴. Resmini et al. observed changes in serum calcium and PTH levels in the fracture group when compared with the control group (or with osteoarthrosis). All patients were vitamin D3-deficient, with no difference between groups⁵. In the present study, PTH was not statistically significant, but we observed a significant reduction in vitamin D values, in addition to ionic and total calcium, in the group with femoral neck fracture. In both groups, the measured vitamin D values were below the standard used by the method. Although there was no statistically significant difference, we observed an increase in alkaline phosphatase in response to a decrease in vitamin D.

The group with femoral neck fractures presented a more debilitated clinical picture, with anemia in the majority of the times and a significant reduction in the values of palmar grip strength (evidencing sarcopenia), besides an increase in free thyroxine, in the attempt of the organism to stimulate the basal cell metabolism. Although significant, the difference found in creatinine is probably associated only with patient stabilization for surgery, since there is a large standard deviation.

Although not strong enough to diagnose patients with bone loss in isolation, large prospective studies correlated bone markers with risk of fractures and prediction of bone loss. Naturally, markers also present fluctuations due to several factors, such as diurnal and nocturnal variations, menstrual period, seasonal variations, age, metabolism and clearance, among other conditions, such as increase after fractures, prolonged stay in the bed, malnutrition, rheumatoid arthritis, connective tissue diseases, multiple mveloma. bone metastases. use of anticonvulsants, corticoids, and heparin. Studies are thus still necessary to indicate the best combination of markers⁷. To avoid these confounding factors, the exams were always collected at the same time of day, there were no women of childbearing age, all of them being menopausal, all patients were older than 60 years, none of them had rheumatoid arthritis, connective tissue disease, multiple myeloma or bone metastases, and no one had used corticosteroids or heparin acutely prior to surgery. In this study, we used clinical, laboratory and densitometric factors to evaluate the patients affected by neck fracture or hip osteoarthrosis. Several parameters evaluated were not statistically significant, despite tendencies, as can be observed in tables 3, 4 and 5.

Patients affected by fractures are generally debilitated, being more exposed to complications such as delirium, infection, iatrogenic complications, which in turn contribute to functional decline, increased nursing care needs and risk of death. Geriatricians should be trained to discover these comorbidities, to identify and manage patients who are at increased risk for adverse outcomes, particularly patients who will be operated on for hip fractures¹⁵; this type of fracture has been described as a "geriatric condition, rather than an orthopedic disease"¹⁶. The present research aims to contribute in this sense.

The authors recognize the difficulties in comparing patients submitted to osteoarthrosis or fracture of the femoral neck. However, the inclusion and exclusion criteria applied established a scientific rigor in this research. The number of individuals evaluated also reflects the difficulty of including patients in the study due to the rigor of the criteria. We corroborate several authors that show the multifactorial nature of the risk factors, and the trends found point to the need for a multidisciplinary medical approach.

We conclude that patients with femoral neck fractures present more advanced age, lower weight and lower BMI than patients with osteoarthrosis. The former also displayed a more debilitated clinical picture, with anemia most of the times and reduction of bone mass and of palmar grip strength, in addition to decreased levels of total and ionic calcium, vitamin D and creatinine, with an increase in free thyroxine.

RESUMO

Objetivo: comparar dados clínicos, laboratoriais e densitométricos de pacientes com osteoartrose e com fratura do colo femoral. **Métodos:** estudo transversal de pacientes com fratura do colo femoral e osteoartrose do quadril, submetidos à artroplastia de quadril. Dados clínicos, laboratoriais e densitométricos foram coletados. **Resultados:** cinquenta e três pacientes foram incluídos, 22 com fraturas do colo femoral e 31 com osteoartrose. Pacientes com fratura do colo do fêmur apresentaram maior idade do que os pacientes com osteoartrose, tendo valores de IMC, densidade mineral óssea e força de preensão palmar (pacientes sarcopênicos) inferiores, estando mais incapacitados neurologicamente e apresentando um pior escore ASA. Entre os vários parâmetros bioquímicos analisados, diferenças estatisticamente significantes foram encontrados no cálcio sérico total, cálcio ionizado, vitamina D, tiroxina livre, eritrócitos, hemoglobina, hematócrito, glóbulos brancos totais, neutrófilos, linfócitos e creatinina entre os dois grupos. **Conclusão:** pacientes com fraturas do colo do fêmur são mais idosos do que pacientes com osteoartrose, apresentam tendências entre os dois grupos. **Conclusão:** pacientes com fraturas do colo do fêmur são mais idosos do que pacientes com osteoartrose, apresentam tendências entre os dois grupos.

Descritores: Artroplastia de Quadril. Osteoartrite. Fraturas do Colo Femoral. Fraturas do Quadril. Densitometria.

REFERENCES

- Flugsrud GB, Nordsletten L, Reinholt FP, Risberg MA, Rydevik K, Uhlig T. [Osteoarthritis]. Tidsskr Nor Laegeforen. 2010;130(21):2136-40.
- Egloff C, Hügle T, Valderrabano V. Biomechanics and pathomechanisms of osteoarthritis. Swiss Med Wkly. 2012;142:w13583.
- Keating JE. Femoral neck fractures. In: Court-Brown CM, Heckman JD, McQueen MM, Ricci WM, Tornetta P, McKee MD, editors. Rockwood and Green's fractures in adults. 8th ed. Philadelphia (PA): Wolters Kluwer Health; 2015.
- Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explains the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87(4):1586-92.
- Resmini G, Migliaccio S, Dalle Carbonare L, Sala U, Brama M, Fornari R, et al. Differential characteristics of bone quality and bone turnover biochemical markers in patients with hip fragility fractures and hip osteoarthritis: results of a clinical pilot study. Aging Clin Exp Res. 2011;23(2):99-105.
- Loeser RF. Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix. Osteoarthritis Cartilage. 2009;17(8):971-9.
- 7. Abramson SB, Attur M. Developments in the scientific understanding of osteoarthritis. Arthritis Res Ther. 2009;11(3):227.

- 8. Loeser RF. Pathogenesis of osteoarthritis [Internet]. Waltham (M): UpToDate; c2017 [updated 2018 Feb 2; cited 2017 Sep 17]. Available from: https://www.uptodate.com/contents/ pathogenesis-of-osteoarthritis?source=search_ result&search=Pathogenesis%20of%20 osteoarthritis%20Kalunian&selectedTitle=3~150
- Todd Allen R, Robertson CM, Harwood FL, Sasho T, Williams SK, Pomerleau AC, et al. Characterization of mature vs aged rabbit articular cartilage: analysis of cell density, apoptosis-related gene expression and mechanisms controlling chondrocyte apoptosis. Osteoarthritis Cartilage. 2004;12(11):917-23.
- Sniekers YH, Weinans H, Bierma-Zeinstra SM, van Leeuwen JP, van Osch GJ. Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment - a systematic approach. Osteoarthritis Cartilage. 2008;16(5):533-41.
- 11. Zeng WN, Wang FY, Chen C, Zhang Y, Gong XY, Zhou K, et al. Investigation of association between hip morphology and prevalence of osteoarthritis. Sci Rep. 2016;6:23477.
- Robbins J, Aragaki AK, Kooperberg C, Watts N, Wactawski-Wende J, Jackson RD, et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA. 2007;298(20):2389-98.
- Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in pre-menopausal and postmenopausal subjects and osteoporotic patients. J Clin Endocrinol Metab.1995;80(8):2447-50.

- 14. Demiaux B, Arlot ME, Chapuy MC, Meunier PJ, Delmas PD. Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings. J Clin Endocrinol Metab. 1992;74(5):1146-51.
- 15. Friedman SM, Mendelson DA, Kates SL, McCann RM. Geriatric co-management of proximal femur fractures: total quality management and protocol-driven care result in better outcomes for a frail patient population. J Am Geriatrics Society. 2008;56(7):1349-56.
- Adunsky A, Arad M, Levi R, Blankstein A, Zeilig G, Mizrachi E. Five-year experience with the 'Sheba'

model of comprehensive orthogeriatric care for elderly hip fracture patients. Disabil Rehabil. 2005;27(18-19):1123-7.

Received in: 08/21/2018

Accepted for publication: 09/20/2018 Conflict of interest: none. Source of funding: Research Incentive Fund (FIPE) of the Hospital de Clinicas of Porto Alegre.

Mailing address:

Leandro de Freitas Spinelli E-mail: spinelli@portoweb.com.br

